Gini F. Fleming

ORCID: 0000-0003-2845-4023 · 4 papers in corpus
nonrandomized-trial 2021
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…

rct 2016
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
Journal of Clinical Oncology ·doi:10.1200/jco.2015.61.2259

PURPOSE: To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus trip…

review 2013
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma
Oncology & hematology review ·doi:10.17925/ohr.2013.09.1.41

Hormonal therapies such as progestins have only modest activity in the treatment of advanced endometrial cancer. Mechanisms of resistance to progestin therapy are not well understood. However, activation of the PI3K/AKT/mTOR pathway has bee…

review 2010
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma
European endocrinology ·doi:10.17925/ee.2013.09.01.18

Hormonal therapies such as progestins have only modest activity in the treatment of advanced endometrial cancer. Mechanisms of resistance to progestin therapy are not well understood. However, activation of the PI3K/AKT/mammalian target of …